

AMENDMENT

U.S. Appln. No. 09/448,378

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-5. (Cancelled).

Claim 6. (Currently Amended) A method for augmenting an tumor-specific immune responses in a patient having a cancerous or neoplastic disease, comprising ~~the steps of~~ administering flt3-ligand to the patient in an amount sufficient to generate an increase in the number of the patient's dendritic cells and administering a tumor antigen to the patient,

wherein the tumor antigen is specific for said disease and wherein the flt3-ligand-derived resulting dendritic cells augment the patient's tumor-specific immune responses to said tumor in said patient,

wherein said flt3-ligand comprises a polypeptide that is at least 90% identical to an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:1 wherein Xaa is an amino acid from 160 to 235, and wherein the polypeptide retains the capacity to bind flt3.

Claim 7. (Currently Amended) AThe method according to claim 6, further comprising ~~the step of~~ administering GM-CSF to the patient.

Claims 8-19. (Cancelled).

Claim 20. (Currently Amended) A method for treating cancerous or neoplastic disease in a patient in need thereof, comprising administering flt3-ligand to the a patient afflicted with a cancer or neoplastic disease, flt3-ligand in an amount

AMENDMENT

U.S. Appln. No. 09/448,378

sufficient to generate an increase in the number of the patient's dendritic cells, and administering a tumor antigen to the patient,

wherein said tumor antigen is specific for said disease
and wherein the flt3-ligand derived resulting dendritic cells
augment the patient's tumor specific immune responses to said
tumor in said patient to thereby treat said disease,

wherein said flt3-ligand comprises a polypeptide that is at
least 90% identical to an amino acid sequence selected from the
group consisting of amino acids 28 to Xaa of SEQ ID NO:1 wherein
Xaa is an amino acid from 160 to 235, and wherein the
polypeptide retains the capacity to bind flt3.

Claim 21. (Cancelled).

Claim 22. (Previously Presented) The method of claim 6, wherein the flt3-ligand is human flt3-ligand.

Claim 23. (Previously Presented) The method of claim 22, wherein the flt3-ligand is soluble human flt3-ligand.

Claim 24. (Previously Presented) The method of claim 23, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

Claim 25-27. (Cancelled).

Claim 28. (Currently Amended) The method of claim 266, wherein the soluble human flt3-ligand comprises the amino acid sequence of residues 28-160 of SEQ ID NO:1.

Claim 29. (Cancelled).

Claim 30. (Currently Amended) The method of claim 266, wherein the soluble human flt3-ligand comprises the amino acid sequence of residues 28-182 of SEQ ID NO:1.

AMENDMENT

U.S. Appln. No. 09/448,378

Claim 31. (Previously Presented) The method of claim 20, wherein the flt3-ligand is human flt3-ligand.

Claim 32. (Previously Presented) The method of claim 31, wherein the flt3-ligand is soluble human flt3-ligand.

Claim 33. (Previously Presented) The method of claim 32, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

Claim 34. (Currently Amended) The method of claim 3320, wherein the human flt3-ligand comprises the amino acid sequence of residues 28-160 of SEQ ID NO:1 ~~wherein the soluble human flt3-ligand comprises a polypeptide that is at least 90% identical to an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:1, wherein Xaa is an amino acid from 160 to 235, and wherein the polypeptide retains the capacity to bind flt3.~~

Claim 35. (Currently Amended) The method of claim 3320, wherein the human flt3-ligand comprises the amino acid sequence of residues 28-182 of SEQ ID NO:1 ~~wherein the soluble human flt3-ligand comprises a polypeptide selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:1, wherein Xaa is an amino acid from 160 to 235, and wherein the polypeptide retains the capacity to bind flt3.~~

Claim 36-39. (Cancelled).

Claim 40. (Previously Presented) The method of claim 6 wherein the cancerous disease is a tumor.

Claim 41. (Previously Presented) The method of claim 20 wherein the cancerous disease is a tumor.

Claim 42. (Previously Presented) The method of claim 40 wherein the tumor is a fibrosarcoma.

AMENDMENT

U.S. Appln. No. 09/448,378

Claim 43. (Previously Presented) The method of claim 41 wherein the tumor is a fibrosarcoma.

Claim 44. (Previously Presented) The method of claim 6, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.

Claim 45. (Previously Presented) The method of claim 6, wherein the tumor antigen is in the form of an isolated tumor antigen.

Claim 46. (Previously Presented) The method of claim 6, wherein the antigen is administered prior to administering flt3-ligand.

Claim 47. (Previously Presented) The method of claim 6, wherein the antigen is administered concurrently with flt3-ligand.

Claim 48. (Previously Presented) The method of claim 6, wherein the antigen is administered after administering flt3-ligand.

Claim 49. (Previously Presented) The method of claim 20, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.

Claim 50. (Previously Presented) The method of claim 20, wherein the tumor antigen is in the form of an isolated tumor antigen.

Claim 51. (Previously Presented) The method of claim 20, wherein the tumor antigen is administered prior to administering flt3-ligand.

Claim 52. (Previously Presented) The method of claim 20, wherein the tumor antigen is administered concurrently with administering flt3-ligand.

AMENDMENT

U.S. Appln. No. 09/448,378

Claim 53. (Previously Presented) The method of claim 20, wherein the tumor antigen is administered after administering flt3-ligand.

Claim 54-56. (Cancelled).